Monocyte HLA-DR expression in septic shock patients: insights from a 20-year real-world cohort of 1023 cases
An erratum to this article was published (Intensive Care Med, Nov 2025 ↗)
Authors' conclusion
This large real-world study confirms that mHLA-DR is a robust enrichment biomarker for identifying the most immunosuppressed septic shock patients at higher risk of adverse outcomes.
Study context
- Population
- Septic shock patients in ICU, mHLA-DR measured by standardized flow cytometry during the first week of ICU admission
- Participants
- 1,023 patients
- Exposure
- Low mHLA-DR vs higher mHLA-DR
- Outcome
- Day-28 and day-90 mortality, and ICU-acquired infections
Methodological detailsreal-world, 20-year cohort
- Real-world
- 20-year cohort
Main finding
As reported in the abstract
Mortality and ICU-acquired infections
- Low mHLA-DR (< 8000 AB/C) significantly associated with increased mortality and ICU-acquired infections
- Association held across static and dynamic measures, multivariate analyses, Kaplan-Meier survival curves, and trajectory clustering (K-means)
Observational data: associations, not effects.
Original publication
Monocyte HLA-DR expression in septic shock patients: insights from a 20-year real-world cohort of 1023 cases. Intensive Care Med. Published 23 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →